BIO-RAD LABORATORIES, INC.
For the period ended Mar 31, 2026. Filed Apr 30, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed Apr 30, 2026
BIO-B$389.98+2.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Income (Loss)
(In millions, except number of shares, which are reflected in thousands, and per share data)
(Unaudited)
| Three Months Ended | ||
|---|---|---|
| March 31, | ||
| 2026 | 2025 | |
| Net sales | $592.1 | $585.4 |
| Cost of goods sold | 282.7 | 279.4 |
| Gross profit | 309.4 | 306.0 |
| Selling, general and administrative expense | 212.4 | 208.8 |
| Research and development expense | 62.9 | 73.5 |
| Income from operations | 34.1 | 23.7 |
| Interest expense | 12.3 | 12.0 |
| Foreign currency exchange gains, net | (2.4) | (2.7) |
| (Gains) losses from change in fair market value of equity securities and loan receivable | 738.2 | (31.8) |
| Other income, net | (24.2) | (37.2) |
| Income (loss) before income taxes | (689.8) | 83.4 |
| (Provision for) benefit from income taxes | 162.7 | (19.4) |
| Net income (loss) | $(527.1) | $64.0 |
| Basic earnings (loss) per share: | ||
| Net income (loss) per basic share | $(19.55) | $2.29 |
| Weighted average common shares - basic | 26,958 | 27,941 |
| Diluted earnings (loss) per share: | ||
| Net income (loss) per diluted share | $(19.55) | $2.29 |
| Weighted average common shares - diluted | 26,958 | 27,955 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.